Group 1 - ARCpoint Inc. has entered into an agreement to sell its 68% ownership interest in Achieve Behavioral Health Greenville LLC for a total consideration of US$480,000, resulting in a net cash payment of US$360,000 after deducting US$120,000 for amounts owed between the parties [1] - The sale is part of a strategy to streamline operations and provide working capital for advancing technology platform integration for CRESSO Brands franchisee locations [7] - The joint venture CRESSO Brands LLC, formed with Any Lab Test Now, combines over 235 franchise locations from ALTN and more than 135 from ARCpoint, making it the largest franchise network of its kind in the United States [2] Group 2 - Achieve Behavioral Health operates under the brand name Vertical Treatment Centers, providing drug and alcohol addiction treatment services in South Carolina [1] - ARCpoint leverages technology and physical locations to offer convenient and cost-effective healthcare solutions with transparent pricing [3]

Core Insights - ONWARD Medical N.V. has received FDA de novo classification and authorization to market its ARC-EX System, the first FDA-approved technology to improve hand strength and sensation after chronic spinal cord injury (SCI) [1][2] - The ARC-EX System is recognized as a Breakthrough Device and was named one of TIME Magazine's Best Inventions of 2024 [1][7] - The device utilizes non-invasive electrical stimulation to enhance spinal cord function, marking a significant advancement in therapies for individuals with chronic SCI [2][7] Company Overview - ONWARD Medical is focused on developing innovative therapies aimed at restoring movement and independence for individuals with spinal cord injuries and other movement disabilities [8] - The company has a pipeline of technologies, including the investigational ARC-IM System and ARC-BCI System, which incorporates brain-computer interface technology [3][8] - The company is headquartered in the Netherlands and has additional facilities in Switzerland and the United States [9] Clinical Impact - The Up-LIFT clinical study demonstrated that 90% of participants improved in strength or function, and 87% reported enhanced quality of life, with benefits observed up to 34 years post-injury [3][6] - Regaining hand function is prioritized significantly higher than other abilities lost due to paralysis, indicating a strong demand for effective therapies in this area [3] Market Authorization and Future Plans - The current FDA authorization is for clinical use, with home use expected to be authorized by mid-2025 [3] - The company plans to seek CE Mark certification for the ARC-EX System in Europe, with expectations for authorization in the second half of 2025 [3]

Core Viewpoint - Nanox Imaging Ltd has received FDA clearance for its Nanox.ARC system, expanding its imaging capabilities to include pulmonary, intra-abdominal, and paranasal indications, in addition to its previous clearance for musculoskeletal imaging [2][4]. Group 1: FDA Clearance and Technology - The Nanox.ARC is a stationary X-ray system designed for general use, now cleared for multiple imaging indications [2]. - It features a proprietary digital X-ray source and advanced tomosynthesis technology, providing a three-dimensional view of the body and reducing the limitations of traditional 2D X-rays [3][4]. - The system is currently deployed in healthcare facilities across seven states in the U.S., with additional units being shipped worldwide [4]. Group 2: Impact on Healthcare Providers - The FDA clearance allows U.S. healthcare providers to access broader imaging capabilities similar to traditional X-ray devices, enhancing patient care [4]. - The technology aims to reduce patient wait times and improve overall diagnostic efficiency, potentially allowing for faster care without the need for separate imaging facilities [5][6]. - The system is designed for integration into existing clinical workflows, operated by trained professionals in various healthcare settings [5]. Group 3: Company Vision and Future Plans - Nanox aims to drive the transition to preventive healthcare through affordable medical imaging technologies, leveraging AI for smarter diagnostics [7][8]. - The company envisions expanding its technology beyond hospital settings, providing a comprehensive solution from scan to diagnosis [8]. - The Nanox ecosystem includes various components such as Nanox.AI for enhanced imaging analysis and Nanox.CLOUD for data management [9].

Grant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after stroke Funding also supports technology development of ARC-BCI System and ARC-IM Lead Approximately 15 million people worldwide experience a stroke each year EINDHOVEN, the Netherlands, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimula ...

Core Viewpoint - A significant shareholder of Trump Media, ARC Global Investments II, has sold nearly its entire stake, reducing its ownership from over 11 million shares (5.4%) to just 30,147 shares (0.01%) as per SEC filings [1][2]. Group 1: Shareholder Actions - ARC Global Investments II and its manager, Patrick Orlando, no longer own more than 5% of Trump Media stock following a substantial sell-off [1]. - The SEC filing indicates that the actions leading to this change occurred on September 30, although the specific timing of the stock sale remains unclear [4]. - The diminished stake of ARC is now valued at approximately $850,000 [3]. Group 2: Legal and Market Context - A Delaware judge ruled in mid-September that Trump Media breached an agreement with ARC, necessitating the granting of additional shares to ARC [3]. - Trump Media experienced a significant sell-off in late summer, with stock prices nearing post-merger lows by the end of September, but saw a recovery in October [5]. - The stock rally in October is attributed to the upcoming presidential election, with many retail investors reportedly buying shares to support Trump [6].

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Oil, Gas, Energy, Metals - That's the core of my research.I am a semi-retired former engineer who switched careers in 2018 to focus on capital management. I acquired most of my knowledge about finance and valuation from NYU Professor Damodaran and books like "Margin of Safety" and "The Intelligent Investor."I specialize in fundamental analysis and require both a deep "Margin of Safety" and a "Catalyst" to consider adding a stock to my portfolio. My portfolio usually contains no more than 10 stocks.I joined ...

[PART I—FINANCIAL INFORMATION](index=6&type=section&id=PART%20I%E2%80%94FINANCIAL%20INFORMATION) [Condensed Consolidated Financial Statements](index=6&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) Presents unaudited condensed consolidated financial statements for Q3 2024, highlighting a net loss, decreased operating cash flow, and a pending merger agreement [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of September 30, 2024, shows total assets increased to $313.5 million, liabilities rose, and cash equivalents decreased to $51.3 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $51,291 | $56,093 | | Accounts receivable, net | $41,896 | $35,775 | | Total current assets | $111,527 | $108,652 | | Total assets | $313,455 | $310,124 | | **Liabilities & Equity** | | | | Total current liabilities | $74,702 | $71,157 | | Long-term debt and finance leases | $52,172 | $53,366 | | Total liabilities | $156,908 | $154,399 | | Total equity | $156,547 | $155,725 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net sales for Q3 2024 increased to $74.4 million, but a surge in SG&A expenses led to a net loss of $0.1 million, impacting diluted EPS Statement of Operations Summary (in thousands, except EPS) | Metric | Q3 2024 | Q3 2023 | Nine Months 2024 | Nine Months 2023 | | :--- | :--- | :--- | :--- | :--- | | Net sales | $74,448 | $71,057 | $220,354 | $212,325 | | Gross profit | $24,759 | $24,149 | $73,954 | $72,250 | | SG&A expenses | $23,268 | $19,269 | $63,681 | $57,764 | | Income from operations | $1,482 | $4,870 | $10,244 | $14,455 | | Net (loss) income | $(101) | $3,121 | $5,398 | $8,935 | | Diluted EPS | $— | $0.07 | $0.13 | $0.21 | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations decreased to $19.2 million for the nine months ended September 30, 2024, with increased investing and financing activities Cash Flow Summary - Nine Months Ended Sep 30 (in thousands) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net cash provided by operating activities | $19,209 | $22,857 | | Net cash used in investing activities | $(10,456) | $(7,461) | | Net cash used in financing activities | $(13,616) | $(17,206) | | Net change in cash and cash equivalents | $(4,802) | $(1,975) | [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Key notes disclose a pending merger agreement, revenue by service line, no goodwill impairment, and an increased site remediation liability of $4.3 million - On August 27, 2024, ARC entered into a merger agreement with TechPrint Holdings, LLC, an entity affiliated with ARC's CEO, COO, and CFO, to be taken private. The transaction is expected to close in Q4 2024[31](index=31&type=chunk)[33](index=33&type=chunk) Net Sales by Service Line (in thousands) | Service Line | Q3 2024 | Q3 2023 | Nine Months 2024 | Nine Months 2023 | | :--- | :--- | :--- | :--- | :--- | | Digital Printing | $46,636 | $43,537 | $136,127 | $129,134 | | MPS | $18,315 | $18,582 | $55,627 | $56,556 | | Scanning & Digital Imaging | $5,354 | $4,991 | $16,676 | $14,845 | | Equipment & Supplies | $4,143 | $3,947 | $11,924 | $11,790 | | **Total Net Sales** | **$74,448** | **$71,057** | **$220,354** | **$212,325** | - The company recorded a site remediation liability of **$4.3 million** as of September 30, 2024, related to a contaminated site acquired in the 1990s. This is an increase from the initial estimate due to newly identified complexities[81](index=81&type=chunk)[83](index=83&type=chunk)[84](index=84&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses 3.8% revenue growth for the first nine months of 2024, increased SG&A due to merger costs, and strong liquidity despite lower net income [Results of Operations](index=26&type=section&id=Results%20of%20Operations) Q3 2024 net sales increased 4.8% to $74.4 million, but surging SG&A expenses, driven by merger costs, resulted in a net loss and reduced EBITDA margin Q3 2024 vs Q3 2023 Performance (in millions) | Metric | Q3 2024 | Q3 2023 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total Net Sales | $74.4 | $71.1 | $3.4 | 4.8% | | Gross Profit | $24.8 | $24.1 | $0.6 | 2.5% | | SG&A Expenses | $23.3 | $19.3 | $4.0 | 20.8% | | Net (Loss) Income | $(0.1) | $3.2 | $(3.2) | (102.1)% | | Adjusted EBITDA | $6.2 | $10.0 | $(3.9) | (38.4)% | - The increase in Selling, General and Administrative (SG&A) expenses for Q3 and the first nine months of 2024 included **$3.2 million** and **$4.1 million**, respectively, of costs related to the pending take-private merger transaction[128](index=128&type=chunk) - The effective tax rate for Q3 2024 was **108.6%**, significantly impacted by non-deductible costs associated with the merger agreement[131](index=131&type=chunk)[132](index=132&type=chunk) [Liquidity and Capital Resources](index=33&type=section&id=Liquidity%20and%20Capital%20Resources) As of September 30, 2024, the company held $51.3 million in cash, with $36.8 million in working capital, and sufficient liquidity for the next twelve months Liquidity Position (in thousands) | Metric | Sep 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $51,291 | $56,093 | | Working capital | $36,825 | $37,495 | | Total debt obligations | $59,148 | $62,236 | - The company's 2021 Credit Agreement, with **$40.0 million** in outstanding revolving loans, will be paid off as part of the transactions contemplated by the Merger Agreement[130](index=130&type=chunk)[185](index=185&type=chunk) - Capital expenditures for the nine months ended September 30, 2024, were **$10.9 million**, an increase from **$7.7 million** in the prior year, as the company chose to purchase more equipment outright due to rising interest rates[168](index=168&type=chunk) [Critical Accounting Policies and Significant Judgements and Estimates](index=37&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgements%20and%20Estimates) No material changes to critical accounting policies, with goodwill confirmed as not impaired and a valuation allowance maintained against deferred tax assets - The annual goodwill impairment test as of September 30, 2024, concluded that the company's **$121.1 million** in goodwill was not impaired[197](index=197&type=chunk)[200](index=200&type=chunk) - A sensitivity analysis showed that a **50-basis point reduction** in projected EBITDA margin or a **50-basis point increase** in the discount rate would not result in goodwill impairment[200](index=200&type=chunk)[201](index=201&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, ARC is exempt from providing disclosures on market risk under Item 3 - As a smaller reporting company, ARC is exempt from providing disclosures on market risk under Item 3[210](index=210&type=chunk) [Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were effective as of September 30, 2024, with no material changes to internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of September 30, 2024[212](index=212&type=chunk) - No changes that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting occurred during the quarter ended September 30, 2024[213](index=213&type=chunk) [PART II—OTHER INFORMATION](index=40&type=section&id=PART%20II%E2%80%94OTHER%20INFORMATION) [Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in routine legal proceedings, with no expected material adverse effect on financial condition or results of operations - The company does not expect current legal proceedings to have a material adverse effect on its results of operations, financial condition, or cash flows[215](index=215&type=chunk) [Risk Factors](index=40&type=page&id=Item%201A.%20Risk%20Factors) Primary risks relate to the pending merger, including potential non-completion, operational uncertainty, and significant transaction-related costs - A key risk is the potential failure to complete the proposed merger, which is subject to stockholder approval and other closing conditions. Failure could result in adverse consequences, including a termination fee of **$5,277,367**[218](index=218&type=chunk)[219](index=219&type=chunk)[220](index=220&type=chunk) - The pending transaction creates uncertainty that may impair the company's ability to retain key employees and could cause customers and suppliers to change or discontinue business relationships[222](index=222&type=chunk) - The merger agreement restricts the company from taking certain actions without the acquirer's consent, potentially preventing it from pursuing attractive business opportunities[226](index=226&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No equity securities were repurchased in Q3 2024, with repurchases restricted due to the pending merger agreement - No shares were repurchased during the quarter from July 1, 2024, to September 30, 2024. The company is restricted from repurchasing shares due to the pending merger agreement[232](index=232&type=chunk) [Other Information](index=42&type=section&id=Item%205.%20Other%20Information) No directors or executive officers adopted or terminated Rule 10b5-1 trading plans during Q3 2024 - No board members or executive officers adopted or terminated Rule 10b5-1 trading plans in Q3 2024[233](index=233&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including the Merger Agreement and CEO/CFO certifications - Key exhibits filed with this report include the Merger Agreement dated August 27, 2024, and related amendments, along with CEO/CFO certifications under SOX Sections 302 and 906[235](index=235&type=chunk) [Signatures](index=44&type=section&id=Signatures) The report was duly signed by the Chairman and CEO, and the CFO, on November 4, 2024 - The report was signed on November 4, 2024, by the company's Chairman and CEO, and its CFO[237](index=237&type=chunk)

ARC Reports Financial Results for Third Quarter 2024 —————————————————————— SAN RAMON, CA – (November 4, 2024) – ARC Document Solutions, Inc. (NYSE: ARC), a leading provider of digital printing and document-related services, today reported its financial results for the third quarter ended September 30, 2024. | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-----------------------------------------|-------|----------|-------|--------------------- ...

ARC Document Solutions (ARC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.06. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this provider of document services to businesses would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise.Over the last four quart ...